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A b s t r a c t
Introduction: PCSK9 inhibitors lower low-density lipoprotein (LDL) choles-
terol and are efficacious at reducing vascular disease, however questions 
remain about potential effects on cognitive function. 
Methods: We examined the association of genetic variants in PCSK9 with 
continuous measures of cognitive ability in UK Biobank. Six independent 
polymorphisms in PCSK9 were used in up to 337,348 individuals. 
Results: The PCSK9 allele score was associated with a lower risk of CHD, and 
weakly with worse log reaction time. 
Conclusions: We are unable to rule out meaningful associations of PCSK9 
genetic variants with cognition, emphasising the potential need for contin-
ued pharmacovigilance for patients currently treated with PCSK9 inhibitors.
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Therapeutic modification of atherogenic lipoproteins by statins [1], eze-
timibe [2] and Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibi-
tion [3] is an effective strategy to reduce the risk of cardiovascular disease 
(CVD), principally by lowering non-HDL-cholesterol [4]. PCSK9 regulates 
LDL-cholesterol (LDL-C) through hepatic expression of LDL receptors. PCSK9 
inhibitors are licensed as LDL-C lowering agents with excellent efficacy and 
evidence of cardiovascular benefits: the FOURIER trial [3] reported that 
a monoclonal antibody to PCSK9 that lowered LDL-C by 59% (~56 mg/dl) led 
to a 15% reduction in the risk of a composite of cardiovascular death, myo-
cardial infarction, stroke, hospitalization for unstable angina or coronary 
revascularization in patients with established atherosclerotic vascular dis-
ease. However, early phase 3 studies showed a potential excess of neuro-
cognitive adverse effects [5], leading the US FDA to instruct pharmaceutical 
companies to assess potential neurocognitive side effects of PCSK9 inhib-
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itors. While, reassuringly, no excess risk was noted 
in the FOURIER trial [3] or its substudy with detailed 
cognitive measures [6], these studies cannot fully 
exclude potential adverse effects from longer-term 
use of PCSK9 inhibitors. An orthogonal approach 
to obtain reliable information is to exploit genetic 
variants that mimic pharmacological inhibition of 
PCSK9. Naturally occurring variation in the gene en-
coding a drug target can be used to gauge insight 
on long-term effects of therapeutic modification [7]. 
So-called drug-target Mendelian randomization [8] 
exploits the characteristics of the genotype for the 
reliable estimation of both intended and unintend-
ed consequences of therapeutic modification of 
a drug target, as previously demonstrated [9–12].
Methods. We used four measures of cognitive 
ability from UK Biobank (UKB) data: two from 
baseline (2006-2010): fluid reasoning measured in 
160,130 individuals (with genetic data, prior to ex-
clusions listed below) and reaction time in 482,187 
as they showed good intra-participant longitudi-
nal reliability in n = 19,999 participants [13], and 
two measured in 2014–2015 via the internet: trail 
making test (TMT) A (processing speed) in 100,587 
and B (speed plus executive function) in 100,610, 
and digit symbol coding (executive function) in 
115,933. TMT and reaction time scores were 
log-transformed due to a positive skew. All mea-
sures were standardized to Z-scores. 
Six independent single nucleotide polymor-
phisms (SNPs) (R2 < 0.15) in PCSK9 (referent al-
lele frequencies rs2479394 A = 0.72; rs11206510 
C = 0.19; rs2479409 A  = 0.65; rs10888897 T = 
0.39; rs7552841 C = 0.63; rs562556 G = 0.18); 
orientated so that the effect allele associated 
with a lower LDL-C were used as genetic variants 
to proxy therapeutic inhibition of PCSK9. SNPs 
were selected from the paper by Ference et al. 
in NEJM [13]. In the paper by Ference et al. [14], 
seven PCSK9 SNPs were used, however two were 
found to be moderately correlated (rs2479409 
and rs2149041; R2 = 0.37). We therefore removed 
the SNP with the weaker association with LDL-C 
(rs2149041) as defined by the p-value [14] leaving 
six SNPs (with pair-wise LD R2 < 0.15) described 
above. The LDL-C association of each of the six 
PCSK9 SNPs from the Global Lipids Genetics Con-
sortium [15] was used to construct a  weighted 
PCSK9 allele score. 
Ethical approval. This secondary-data analysis 
study was conducted under the generic approv-
al from the NHS National Research Ethics Service 
(approval letter dated 17th June 2011, ref. 11/
NW/0382). Written informed consent was ob-
tained from all participants in the study (consent 
for research, by UK Biobank).
Statistical analysis. Linear regression analy-
ses used the four cognition traits as dependent 
variables, the weighted PCSK9 score as the inde-
pendent variable, adjusted for age, sex, GWAS ar-
ray, and 10 principal components (as provided by 
UKB). To mimic pharmacological modification of 
PCSK9, we report results of the PCSK9 allele score 
scaled to the 50 mg/dl lower LDL-C achieved in 
FOURIER. We compared estimates of the PCSK9 al-
lele score with cognition traits to those from APOE 
e4 dosage (excluding rare APOE e2/e4), APOE 
e4/e4 vs. e3/e3 homozygosity; current vs. never 
smoking, and 5-years of increased cross-sectional 
age with cognitive traits. As a further positive con-
trol, we tested the association of the PCSK9 allele 
score with the risk of CHD in UK Biobank (defined 
as self-reported physician-diagnosed myocardial 
infarction and angina).
We excluded participants with non-white Brit-
ish ancestry, self-report vs. genetic sex mismatch, 
putative sex chromosomal aneuploidy, excess 
heterozygosity, and missingness rate > 0.1. We 
removed one random participant in cases where 
two individuals were first cousins or closer. Stata 
v14 and PLINK v1.90 were used for analyses. 
Data availability statement. UK Biobank is an 
open access resource available to verified research-
ers upon application (http://www.ukbiobank.
ac.uk/). Analysis syntax is available upon request.
Results. The PCSK9 allele score scaled to 
a 50 mg/dl lower LDL-C was associated with a low-
er risk of CHD in UKB (comprising 15,284 cases of 
myocardial infarction and angina in 338,852 indi-
viduals; OR = 0.73; 95% CI: 0.60–0.90, p = 0.003). 
We next investigated the associations of six 
variants in PCSK9 scaled to 50 mg/dl lower LDL-C 
in 109,870 individuals with measures of fluid rea-
soning, 337,348 with reaction time, 73,044 with 
processing speed (TMT A), 73,063 with process-
ing speed plus executive function (TMT B), and 
82,012 with digit symbol coding (executive func-
tion) (Figure 1).
Orientated to a 50 mg/dl lower LDL-C (i.e. mim-
icking pharmacological inhibition of PCSK9), the 
PCSK9 allele score was nominally associated with 
log reaction time (0.04 SDs higher log reaction 
time; 95% CI: 0.002–0.079; p = 0.038). For fluid 
reasoning, the scaled PCSK9 allele score had wide 
95% CI (–0.08, 0.07) that included the estimates 
for the association of 5 years additional age (–0.05 
SDs, 95% CI: –0.06, –0.05). Similar patterns were 
identified for all other cognition traits, meaning 
that despite the large sample size, the imprecision 
around the estimates obtained from the PCSK9 al-
lele score meant that we could not exclude a sim-
ilar magnitude of effect of genetic inhibition of 
PCSK9 to that seen with the positive controls, in-
cluding APOE e4 or smoking status for any of the 
individual cognition traits (Figure 1). Notably, point 
estimates for the association of the PCSK9 allele 
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score and all cognitive ability end-points were on 
the harmful side of unity. In sensitivity analyses, 
removal of participants that self-reported a neuro-
logical condition (~5% of the dataset) [13] did not 
alter the findings, nor did substituting rs2479409 
for rs2149041 in the PCSK9 allele score.
Discussion. In this large-scale analysis of in-
dividuals from the general population, we used 
naturally occurring genetic variants in PCSK9 to 
gauge insight into the effect of lifelong lowering 
of LDL-C through inhibition of PCSK9 and its as-
sociation with cognition abilities. Using available 
data in UKB, we were not able to provide defini-
tive evidence on the relationship of PCSK9 genetic 
variants with cognition traits. While this may have 
arisen due to lack of power, we note firstly that 
we were able to show associations of the PCSK9 
allele score with the risk of prevalent self-report-
ed CHD, and secondly robust associations of con-
ventional risk factors (e.g. age and smoking) and 
genetic variants (e.g. APOE e4) with the cognitive 
traits. These observations suggest validity of the 
PCSK9 genetic score as an instrument, and suf-
ficient statistical power for detecting association 
with relevant traits. 
Our findings add to previous studies of genet-
ically-estimated PCSK9 and cognition: Schmidt 
et al. [16] reported no significant association in 
nine cohorts, three of which indexed cognition 
with a  screening tool (Mini-mental state exam) 
rather than normative-range tests as per here; 
while Rao et al. reported no effect on a single cog-
nitive test (Trail-making; processing speed and 
executive function) [17]. The cognitive tests used 
here were novel, brief and bespoke to UK Biobank 
baseline assessment [13], and therefore examina-
tions of cognitive assessments which are based 
on more traditional and validated tasks, may be 
informative. Such analyses may also test for po-
tential age- and sex-specific associations. 
While the imprecision makes it challenging to 
draw firm conclusions about an effect (or lack 
thereof) of life-long LDL-cholesterol lowering by 
PCSK9 inhibition on cognition, our data highlight 
the need for additional large-scale genetic anal-
yses. In parallel, continued pharmacovigilance is 
Figure 1. Association of a PCSK9 allele score (in gray) scaled to 50 mg/dl lower LDL-cholesterol and other selected 
exposures (in black) with cognitive traits in UK Biobank
Cognition trait; genotype exposure Standardized β  P-value
 (95% CI)
Log reaction time (n = 337,348) 
PCSK9 weighted score (per 50 mg/dl lower LDL-C) 0.04 (0.00, 0.08)  0.038 
APOE (per e4 allele) 0.00 (–0.00, 0.01)  0.658 
APOE (e4e4 vs. e3e3) 0.02 (–0.00, 0.04)  0.133
Smoking (current vs. never) 0.06 (0.06, 0.07) < 0.001
Per 5-years of age 0.20 (0.19, 0.20) < 0.001
Fluid reasoning scores (n = 109,870) 
PCSK9 weighted score (per 50 mg/dl lower LDL-C) –0.00 (–0.08, 0.07) 0.89
APOE (per e4 allele) 0.00 (–0.01, 0.01) 0.731 
APOE (e4e4 vs. e3e3) –0.01 (–0.05, 0.03) 0.731
Smoking (current vs. never) –0.12 (–0.13, –0.11) < 0.001
Per 5-years of age –0.05 (–0.06, –0.05) < 0.001
Log trail making test a (n = 73,044)
PCSK9 weighted score (per 50 mg/dl lower LDL-C) 0.03 (–0.05, 0.12) 0.435
APOE (per e4 allele) 0.02 (0.01, 0.04) 0.001
APOE (e4e4 vs. e3e3) 0.04 (–0.01, 0.09) 0.103
Smoking (current vs. never) 0.05 (0.03, 0.06) < 0.001
Per 5-years of age 0.19 (0.19, 0.20) < 0.001
Log Trail making test b (n = 73,063) 
PCSK9 weighted score (per 50 mg/dl lower LDL-C) 0.04 (–0.04, 0.12) 0.352
APOE (per e4 allele) 0.04 (0.03, 0.05) < 0.001
APOE (e4e4 vs. e3e3) 0.09 (0.04, 0.13) < 0.001
Smoking (current vs. never) 0.10 (0.09, 0.12) < 0.001
Per 5-years of age 0.24 (0.23, 0.24) < 0.001 
Digit Symbol coding scores (n = 82,012) 
PCSK9 weighted score (per 50 mg/dl lower LDL-C) –0.04 (–0.11, 0.04) 0.352 
APOE (per e4 allele) –0.05 (–0.06, –0.03) < 0.001
APOE (e4e4 vs. e3e3) –0.13 (–0.17, –0.09) < 0.001
Smoking (current vs. never) –0.08 (–0.09, –0.07) < 0.001
Per 5-years of age –0.26 (–0.26, –0.25) < 0.001 
 –0.3 –0.2 –0.1 0 0.1 0.2 0.3 
Standardized β of cognition trait
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potentially needed for patients currently treated 
with PCSK9 inhibitors. 
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